Perceptive Bioscience Investments Ltd, a London, UK-based health and life sciences company investing in medical innovation, has started operations with initial funding (of undisclosed amount).
Backers included Woodford Investment Management and other institutional investors.
Formed by Dr Joe Anderson, Chief Executive Officer (formerly a partner with Abingworth LLP), Jonathan Peacock, Chairman (formerly CFO of Amgen and Novartis Pharma) and Professor Sir Christopher Evans, OBE, Deputy Chairman (one of Europe’s most successful entrepreneurs), Perceptive Bioscience Investments has developed a broad investment strategy providing seed, venture and growth capital as well as private and public equity.
The company’s evergreen structure permits further capital raising, which will continue as breakthrough science and high potential life sciences investment opportunities worldwide arise.
Headquartered in London with offices in New York, Perceptive has already secured relationships with science-based universities in the UK, EU and Australia as well as in the US through an established network of leading academic centres and companies.